Biopendium subscription with Aventis

Published: 26-Nov-2003


Inpharmatica, the selective drug discovery company, has entered into a non-exclusive multi user agreement with Aventis for Inpharmatica's Biopendium its premier proteome annotation resource that can play a key role in accelerating drug discovery.

Under the terms of the agreement Biopendium will be installed onsite at Aventis. It will allow Aventis researchers instant access to 10bn pre-calculated protein relationships derived from over 1.4m sequences from 150 different genomes, integrating structural and ligand information. Commenting on the announcement, Dr Malcolm Weir, CEO at Inpharmatica, said: 'We are delighted to announce that a company of the calibre of Aventis has become the latest subscriber to Biopendium. The fact that we continue to sign major agreements for the on-site version while simultaneously signing agreements for the remotely accessible online version of the database means that the number of users of the database continues to grow, and points to a bright future for this valuable research tool.'

  

You may also like